The chart below shows the treatments the researchers planned to study. The doses of tezepelumab were measured in milligrams, also called "mg".

Group 1 Group 2 Group 3 Placebo
12 participants 12 participants 12 participants 12 participants
70 mg of 210 mg of 420 mg of placebo
tezepelumab tezepelumab tezepelumab

A single injection under the skin

What happened during this study?

The study started in May 2020 and ended in October 2020.

Before the participants got study treatment, they visited their study site 1 time. This part of the study lasted for up to 4 weeks. At this visit, the study doctors made sure the participants could join the study. They also:

- Did physical exams and asked about the participants' medications and any medical problems they were having
- Took blood and urine samples
- Checked the participants' heart health using an electrocardiogram, also called an ECG

The study doctors also did these tests and measurements throughout the study.

While the participants got study treatment, they visited their study site 1 time. This part of the study lasted for 3 days. The participants stayed at the study site for 2 nights. They got a single injection of their study treatment on the second day of their stay.

After the participants got study treatment, they visited their study site 12 times. At these visits, the study doctors checked the health of the participants and took blood samples. This part of the study lasted for up to 16 weeks.

Clinical Study Results